Infosys rises on completing acquisition of Optimum Healthcare IT

Infosys Ltd. | IT - Software | IT & ITES | BSE: 500209 | NSE: INFY

05 May 2026 Evaluate

Infosys is currently trading at Rs. 1172.65, up by 4.25 points or 0.36% from its previous closing of Rs. 1168.40 on the BSE.

The scrip opened at Rs. 1168.40 and has touched a high and low of Rs. 1185.00 and Rs. 1160.50 respectively. So far 111083 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1727.85 on 03-Feb-2026 and a 52 week low of Rs. 1149.80 on 28-Apr-2026.

Last one week high and low of the scrip stood at Rs. 1,377.30 and Rs. 1,149.80 respectively. The current market cap of the company is Rs. 477022.42 crore.

The promoters holding in the company stood at 14.38%, while Institutions and Non-Institutions held 71.85% and 13.76% respectively.

Infosys has completed the acquisition of Optimum Healthcare IT, recognized as a Best in KLAS healthcare digital transformation and consulting firm known for helping provider organizations drive large-scale transformation.

The acquisition of Optimum Healthcare IT underscores Infosys’ commitment to strengthening its healthcare capabilities, particularly in collaboration with health systems and provider organizations to deliver measurable outcomes across complex clinical and operational environments. Optimum Healthcare IT brings deep provider-domain expertise and a proven delivery model - making it a strong strategic fit for Infosys’ healthcare growth strategy. This investment significantly enhances Infosys’ presence in the provider segment, adding new clients and relationships, expanding technology capabilities, and creating synergies across new buying centers. By bringing together Optimum’s provider experience with Infosys Topaz and Infosys Cobalt, it is positioned to create a differentiated value proposition for healthcare providers - accelerating end-to-end cloud, data, and digital transformation at scale.

Together, Infosys and Optimum Healthcare IT will unlock AI-powered, large-scale cloud and data transformation initiatives for healthcare providers through an integrated, end-to-end set of offerings- supporting improved patient experiences through data-driven, personalized care while driving greater operational efficiency and cost optimization.

Infosys is a leading provider of consulting, technology, outsourcing and next-generation digital services, enabling clients to execute strategies for their digital transformation.

Infosys Share Price

1170.85 3.55 (0.30%)

07-May-2026 12:53 View Price Chart

Peers

Company Name	CMP
TCS	2411.75
Infosys	1170.85
HCL Tech.	1189.00
Wipro	198.00
Tech Mahindra	1456.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.